Global Next-Generation Antibody Therapies Market Forecast 2018-2028 - Visiongain Report

LONDON, October 2, 2018 /PRNewswire/ --

Antibody-Drug Conjugates, Engineered Antibodies, Bispecific Antibodies, Antibody Fragments & ALPs, Biosimilar Antibodies 

The global next-generation antibody therapies market reached $4bn in 2017 and is estimated to reach $17bn by 2023. In 2017, the antibody-drug conjugates segment held 45% of the global next-generation antibody therapies market.

     (Logo: https://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg )

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 217-page report you will receive 141 charts- all unavailable elsewhere.

The 217-page report provides clear detailed insight into the next-generation antibody therapies market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope 

• Global Next-Generation Antibody Therapies Market from 2018-2028

• Forecast of the Global Next-Generation Antibody Therapies market by Submarket:
• Antibody Fragments & ALPs
• Antibody-Drug Conjugates
• Biosimilar Antibodies
• Bispecific Antibodies
• Engineered Antibodies

• Forecast of the Global Antibody Fragments & ALPs submarket by Product:

• Kalbitor

• Other Antibody Fragments

• Forecast of the Global Antibody-Drug Conjugates submarket by Product:

• Adcetris

• Kadcyla

• Mylotarg

• Other ADCs

• Forecast of the Global Biosimilar Antibodies submarket by Product:

• Infliximab

• Adalimumab

• Rituximab

• Bevacizumab

• Trastuzumab

• Other Biosimilar mAbs

• Forecast of the Global Bispecific Antibodies submarket by Product:

• Blincyto

• Hemlibra

• Other Bispecific Antibodies

• Forecast of the Global Engineered Antibodies submarket by Product:

• Gazyva/Gazyvaro

• Poteligeo

• Fasenra

• Other Engineered Antibodies

• This report provides individual revenue forecasts to 2028 for these regional and national markets:
• North America: US, Canada, and Mexico
• Europe: Germany, France, United Kingdom, Italy, Spain, Russia, and rest of Europe
• Asia-Pacific: Japan, China, Australia, South Korea, India, and rest of Asia-Pacific
• LAMEA: Brazil, Saudi Arabia, Republic of South Africa, Turkey, and rest of LAMEA

• Our study discusses the selected leading companies that are the major players in the next-generation antibody therapies market:

• Amgen, Inc.

• GlaxoSmithKline (GSK)

• Kirin Holdings (Kyowa Hakko Kirin Co., Ltd.)

• Merck KGaA

• Novartis AG

• Pfizer, Inc.

• Roche

• Sanofi

• Seattle Genetics, Inc.

• Shire plc

• This report discusses SWOT & STEP analysis of the next-generation antibody therapies market as well as factors that drive and restrain this market. This report also discusses the opportunities that can be tapped in this market.

• This report also discusses selected at that are in the pipeline.

Visiongain's study is intended for anyone requiring commercial analyses for the next-generation antibody therapies market. You find data, trends and predictions.

Buy our report today Global Next-Generation Antibody Therapies Market Forecast 2018-2028: Antibody-Drug Conjugates, Engineered Antibodies, Bispecific Antibodies, Antibody Fragments & ALPs, Biosimilar Antibodies

To request a report overview of this report please contact Sara Peerun at [email protected] or refer to our website: https://www.visiongain.com/report/global-next-generation-antibody-therapies-market-forecast-2018-2028/

AbbVie

AbGenomics

Ablynx

AdAlta

ADC Therapeutics

Adnexus

Affimed Therapeutics

Agensys

Alcon

Alexion

Algeta ASA

Allergan

ALMAC Group

Ambrx

Amgen

arGEN-X

Astellas Pharma

AstraZeneca

Bayer

Biogen Idec

BioNet Ventures

Biotest

BioWa

Boehringer Ingelheim

Bristol-Myers Squibb

Cancer Drugs Fund

CARBOGEN AMCIS

Cascadian Therapeutics, Inc.

Catalent Pharma Solutions

Celgene

Celldex Therapeutics

Cephalon

Cilag GmbH International

Clovis Oncology

Coldstream Laboratories

Concortis Biosystems

Corixa

Covagen

Crescendo Biologics

CSL Behring

CVie Therapeutics

CytomX Therapeutics

Daiichi Sankyo

Defiante Farmaceutica

Delenex Therapeutics

Domantis

Dutalys

Dyax

Eddingpharm

Eisai

Eli Lilly

Emergent BioSolutions

Endo Pharmaceuticals

ESBATech

Esperance Pharmaceuticals

ETH Zurich

FDA

Five Prime Therapeutics

Formation Biologics

Fresenius Biotech

F-Star

Fujifilm

Genentech

Genmab

Gilead Sciences

Glenmark

Glycart

Glycotope

Goodwin Biotechnology

GSK

Health Canada

Igenica

Immune Design

Immunocore

ImmunoGen

Immunomedics

IONTAS

Janssen Biotech

Jazz Pharmaceuticals

Kalobios
Karolinska Institute

Kyowa Hakko Kirin

Kyowa Medex

LINDIS Biotech

Lonza

MacroGenics

MedImmune

Merck

Merrimack Pharmaceuticals

Mersana Therapeutics

Merus

Micromet

Millennium Pharmaceuticals

Molecular Partners

MorphoSys

MultiCell Immunotherapeutics (MCIT)

National Institute of Diabetes and Digestive and Kidney Diseases

Neopharm

Neovii Biotech

Nerviano Medical Sciences

NHS

NICE

NMS Group

Nordic Nanovector ASA

Novartis

Novartis Institutes for BioMedical Research (NIBR)

NovImmune

Oxford BioTherapeutics

Oxis Biotech

Pfizer

Pharmacyclics

Pieris

Piramal Enterprises

Piramal Healthcare

PolyTherics

ProBioGen

Progenics

ProStrakan

Redwood BioScience

Roche

Salix

Sanofi

Scil Proteins

Seattle Genetics

Servier

Shinogi

Shire

Sigma-Tau

Simcere Pharmaceutical Group

Sorrento Therapeutics

Spectrum Pharmaceuticals

Spirogen

Stelis Biopharma

Stemcentrx

Strides Arcolab

Sutro Biopharma

Swedish Orphan Biovitrum (Sobi)
Swiss Federal Institute of Technology

Synthon

Synthon Biopharmaceuticals

Takeda

Talon Therapeutics

Teva

TG Therapeutics

The American Society of Hematology

The University of Texas MD Anderson Cancer Center

TRION Pharma

UCB

WHO

Wyeth

Xencor

Zydus Cadila

Zymeworks

To see a report overview please e-mail Sara Peerun on [email protected]

SOURCE Visiongain